{
    "nctId": "NCT02156648",
    "briefTitle": "A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma",
    "officialTitle": "A Feasibility Study for Women Receiving Adjuvant or Neo-adjuvant Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Recruitment rates",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Stage I-III, HER2-neu positive invasive ductal carcinoma\n2. Scheduled to receive adjuvant/neo-adjuvant 5-Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel (FEC-D) chemotherapy\n3. Scheduled to receive adjuvant Trastuzumab\n4. ECOG Performance status 0-2\n5. Adequate baseline imaging on transthoracic echocardiography, and baseline cardiac ejection fraction of \u2265 55%. Additionally, breast cancer patients\u226545 years of age and scheduled to receive whole breast radiation therapy will receive two cardiac PET scans.\n\nExclusion Criteria:\n\n1. Prior anthracycline chemotherapy\n2. History of dilated cardiomyopathy, congestive heart failure, or coronary artery disease\n3. Life expectancy less than 15 months\n4. Pregnant or lactating women\n5. Use of beta receptor antagonists, calcium channel antagonists, angiotensin converting enzyme inhibitors, or angiotensin receptor inhibitors at baseline.\n6. Previous chest wall/breast or nodal radiation.",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}